CYTOMX THERAPEUTICS INC
CytomX Therapeutics Inc., a pioneering biotechnology firm headquartered in the United States, is at the forefront of developing innovative cancer therapies. Founded in 2011, the company has made significant strides in the field of protein engineering, focusing on its proprietary Probody™ platform, which enables the creation of targeted therapies that minimise off-target effects. CytomX operates primarily in the oncology sector, with a commitment to advancing treatments that enhance patient outcomes. The company has achieved notable milestones, including strategic partnerships with major pharmaceutical firms, which bolster its position in the competitive biopharmaceutical landscape. With a robust pipeline of unique therapeutics, CytomX Therapeutics continues to redefine cancer treatment paradigms, making it a key player in the industry.
DitchCarbon Score
How does CYTOMX THERAPEUTICS INC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
CYTOMX THERAPEUTICS INC's score of 25 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
CYTOMX THERAPEUTICS INC's reported carbon emissions
CytomX Therapeutics Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As of now, CytomX Therapeutics has not inherited any emissions data from a parent or related organization, nor does it have any cascading climate initiatives from other entities. This lack of reported emissions and commitments suggests that the company may still be in the early stages of developing a comprehensive climate strategy. In the context of the biotechnology industry, it is increasingly important for companies to establish clear climate commitments and reduction targets to align with global sustainability goals. Without specific data or initiatives, CytomX Therapeutics may face challenges in demonstrating its commitment to reducing carbon emissions and addressing climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
CYTOMX THERAPEUTICS INC is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
